Pancreatic Cancer Research

Clinical trialPhase 2Unknown

A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer

Gimatecan (ST1481) as Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Randomized, Controlled Phase II Study

Outcome
Outcome unknown
Phase
Phase 2
Status
Unknown
Study type
Interventional
Start
1 December 2020
Listed end
1 December 2023
Enrollment
60 participants
Sites
1
Primary outcomes
Progression free survival (PFS)
Sponsor type
Industry
Results posted
No
Last update
1 October 2020

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase II clinical trial studies the safety and effect of as second-line treatmen in local advanced or metastatic pancreatic cancer. The Gimatecan will be given every four weeks.